Goodwin Procter has advised Jefferies LLC, Jefferies GmbH, TD Cowen, Stifel, Nicolaus & Company, Incorporated, Stifel Europe Securities, Van Lanschot Kempen (USA) Inc., and Van Lanschot...
Valneva Completes €84 Million Private Placement
Avalo Therapeutics Launches $430 Million Public Offering of Common Stock and Warrants
Goodwin Procter LLP has advised Avalo Therapeutics. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. has advised the underwriters. Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a...
Medincell Completes €48 Million Private Placement
Goodwin has advised Jefferies, Leerink Partners, Evercore ISI, and Oddo BHF SCA on the transaction. Ashurst advised MedinCell SA. Medincell SA has completed a private placement,...
Kymera Therapeutics Completes $692.3 Million Public Offering
Goodwin Procter has advised Kymera Therapeutics. WilmerHale has advised the underwriters. Kymera Therapeutics, a clinical-stage biotechnology company listed on NASDAQ (KYMR), has completed an upsized public...
Scholar Rock’s $92.5 Million Common Stock Offering
Goodwin advised Scholar Rock Holding Corporation on the offering. Scholar Rock Holding Corporation (Nasdaq: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious...
ReNAgade Therapeutics’ $300 Million Series A Financing Round
Goodwin advised ReNAgade Therapeutics on the fundraising. ReNAgade Therapeutics announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures. ReNAgade has...
BridgeBio Pharma’s $150 Million Common Stock Public Offering
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
Scholar Rock Holding Corporation’s $205 Million Shares Offering
Goodwin Procter advised Scholar Rock Holding Corporation on the deal. Scholar Rock Holding Corporation announced the completion of its registered direct offering of 16,326,530 shares of common...
Senti Biosciences’ Business Combination with Dynamics Special Purpose Corp.
Goodwin Procter advised Senti Biosciences, while Davis Polk advised Dynamics Special Purpose Corp. on the deal. Senti Biosciences (“Senti Bio”) announced its definitive business combination agreement with...
Cronos Group’s Investment in PharmaCann
Fox Rothschild LLP advised PharmaCann on the deal. Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) and PharmaCann Inc. (“PharmaCann”), one of the largest vertically integrated cannabis companies...